Trials / Completed
CompletedNCT04390698
Opioid Free Anesthesia in Breast Cancer Surgery
Opioid Free Anesthesia in Breast Cancer Surgery: a Prospective Randomized Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of incidences of postoperative nausea and vomiting (PONV) , postoperative pain severity and recovery parameters in breast cancer patients receiving opioid or opioid-free general anesthesia.
Detailed description
Breast cancer is one of the most common oncologic diagnosis in women. Surgery is traditionally performed under general anesthesia with opioid-based analgesia. It is associated with higher incidences of PONV, more severe acute postoperative pain and increased incidences of chronic pain. The possibility of higher risk of metastasis has also been reported. The purpose of our study is to compare the opioid-free general anesthesia with the opioid-based general anesthesia with respect to the quality of recovery, postoperative pain and cancer recurrence and metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | paravertebral block | Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site. |
| DRUG | opioid free anesthesia | propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained. |
| PROCEDURE | sham block | Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site. |
| PROCEDURE | opioid general anesthesia | propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained . |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-03-15
- Completion
- 2022-03-15
- First posted
- 2020-05-15
- Last updated
- 2022-04-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04390698. Inclusion in this directory is not an endorsement.